Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
about
A nonimmunosuppressant approach on Asia psoriasis subjects: 5-year followup and 11-year data analysisNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastCytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityAnti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseAnti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseEmerging therapies for the treatment of psoriasisThe emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsCirculating Th17, Th22, and Th1 cells are increased in psoriasisUstekinumabFlavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related DiseasesComparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesTh17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut MicrobiomeA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisUstekinumab for the treatment of Crohn's disease: can it find its niche?Hepatic manifestations of non-steroidal inflammatory bowel disease therapyReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPouring fuel on the fire: Th17 cells, the environment, and autoimmunityReview: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyondAdvances in the treatment of polyarticular juvenile idiopathic arthritisHydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeuticsInflammatory pathways of importance for management of inflammatory bowel diseaseInterleukin-23: as a drug target for autoimmune inflammatory diseasesPutting together the psoriasis puzzle: an update on developing targeted therapiesUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyNew targets in psoriatic arthritisTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabRecent advances in the genetics of autoimmune diseaseIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisApilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review.Evidence: philosophy of science meets medicine.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
P2860
Q21296668-86D17991-BACD-4DD1-9D11-55B83625C951Q22305855-EB63701F-495E-4501-BDBC-FC6E604F104CQ22306446-65314835-C8AD-4E45-BB6A-F98282FF7975Q24188040-D38B511E-BAB9-4EA3-A7DD-5FCC7221F2ACQ24240678-A4019D27-39A0-4C11-960D-7FB5FA26CBE9Q24605738-D7D1DD60-AB09-4C93-BBE1-9EF5F0AD6AA4Q24623195-EBB40C44-1E42-4BE3-AA47-7A5D531FECA7Q24629315-4B8047CC-1FFD-40ED-99D5-0994A7CCA3E5Q24651927-25E2FB51-CFBB-4140-97E7-DBF04EEE81F4Q26746303-F82CD13F-E3CC-4879-A9E6-CE3E18B29ED7Q26764820-FC650C8C-F65B-4FA2-B700-93193EF99C10Q26764867-1C337855-E2CD-40C8-AE5F-B81A7CCE37F5Q26769612-E8DAA4CD-E821-4AE1-AE12-B9C31E9112B9Q26771682-CC1DC27A-C89C-478D-8BE0-B83F7CCA36B7Q26771890-53663B37-71BC-4F90-8DBE-3E92C71CB4CFQ26773684-ACAC47DE-2C7D-4D3F-9E48-FD64E7F93092Q26822029-D6A1B08B-A7BC-46E4-8260-863951418DBBQ26825174-3126702F-E095-42D1-A7C7-C4F4533D1179Q26827714-59D2F2E9-DAD9-4220-8970-2C3DEAA1850CQ26863295-F8A0368B-ADD3-4DE2-A9C8-8E3B329AEBD0Q26991709-7AEF0770-9911-47BE-820B-68FAE1B9DA3CQ27001017-30165E6D-CAF9-4DCA-AC4E-382BE163D665Q27004640-4B2E2E95-F846-4498-85B1-F4B66408D511Q27005445-4735D737-DD87-4683-B7C1-799F11C6A58BQ27009502-2C1F92B5-941F-4177-A835-C96DFA9EE026Q27026785-F28443D1-1BB3-4FF6-86E0-24FB5B15C541Q28067631-7BC4493D-6D3E-4F54-8F10-43EFA7B2AD7CQ28069592-910C9C7E-1C87-401E-B41F-4AF8EBE6F294Q28069819-7CE6786A-6B9A-43D3-A13B-9277DD704D2BQ28238782-81D31EA4-C2D9-44ED-81F5-9D3FBFC5216FQ28268370-D1E5F139-B083-4B1F-89F0-A155EC27DDC5Q28280687-B09DF45D-B70E-4468-9636-6A86D13E3CC4Q28482161-6DDE6B72-24F8-498C-B32D-70C4CB834BEBQ30235581-9DE6823E-0471-4CCD-987F-7D7F679A7C78Q30251957-85F675D4-251F-4015-BCE5-41C5CB41EAC9Q30387690-BAE9E562-AD45-444F-94F1-B55FABBA929DQ30412650-AC2EF20A-119C-44CF-87A2-85D1A8F95272Q30542069-BB13ADA2-E54F-4837-B7B5-E8612593AF64Q30574065-B2F854CA-A457-4C67-B7D3-2B1D966C3E57Q30577671-F2B627B5-303C-4EA4-BEE9-7D8632154965
P2860
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@nl
type
label
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@nl
prefLabel
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@nl
P2093
P921
P3181
P1433
P1476
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 2)
@en
P2093
Cynthia Guzzo
Gerald G Krueger
Kim A Papp
Kristian Reich
Lisa T Dooley
Mark Lebwohl
Ming-Chun Hsu
Newman Yeilding
Philippe Szapary
Richard G Langley
P304
P3181
P356
10.1016/S0140-6736(08)60726-6
P407
P577
2008-05-17T00:00:00Z